Promising Results of Transcatheter Mitral Valve Replacement in Bioprosthesis Failure

Failure of a mitral bioprosthesis always poses a challenge regarding decision-making, especially when dealing with elderly patients with multiple risk factors. The scenario is worsened by the high risk associated with a new sternotomy and the significant impact of undergoing new surgery.

Reemplazo Mitral Transcatéter en Fallas de Bioprótesis

Transcatheter mitral valve-in-valve (TMViV) replacement is emerging as a valid strategy in the aforementioned cases of bioprosthesis failure. However, unfortunately, we currently lack comprehensive analyses and large-scale randomized studies.

In this study, researchers conducted an analysis of 20 consecutive symptomatic patients who underwent TMViV replacement due to bioprosthesis failure.

Subjects with mitral annulus, annular calcification in the surgical bioprosthesis, or a transapical percutaneous valve were excluded.

The average age was 64 years, and 12 patients were women. More than half of the patients had diabetes, preserved renal function, an STS Score of 8.1%, and a EuroSCORE II of 9.2%.

Read also: Clopidogrel Monotherapy Beyond 12 months: Long Term Analysis of the STOPDAPT-2.

Before the procedure, ejection fraction was 44%, with a mean gradient of 13 mmHg. Bioprosthesis failure presented as stenosis with regurgitation in 12 patients, stenosis alone in 5 cases, and regurgitation alone in 2.

The procedure was successful in all patients, with no mortality, infarcton, or stroke. Three patients experienced major bleeding, one required automatic implantable cardioverter defibrillator (AICD), another needed dialysis, and the average hospital stay was 7 days.

Mortality at 30 days and one year was 1 patient and 2 patients, respectively.

Read also: Use of Apixaban and Post TAVR Valve Thrombosis.

After one year of follow-up, all patients were in functional classes I-II, with a gradient of 6 mmHg and an ejection fraction of 44%. All continued anticoagulation.

Conclusion

TMViM replacement with Meril Myval can be performed safely, with high technical success and low mortality at 30 days and one year.

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: Clinical Outcomes Following Transcatheter Mitral Valve-in-Valve Replacement Using a Meril Myval Transcatheter Heart Valve.

Reference: Mullasari Ajit Sankardas, et al. Heart, Lung and Circulation (2023) , article in press.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

TAVR and Surgical Bailout: Temporal Trends and Clinical Implications

The evolution of transcatheter aortic valve replacement (TAVR), both regarding its planning and execution, has resulted in minimally invasive interventions with high safety levels....

Edge-to-Edge Repair in Atrial Secondary Tricuspid Regurgitation

Tricuspid regurgitation (TR) has been associated with higher morbimortality and a negative impact on quality of life.  In most cases, its main cause is a...

Percutaneous Treatment of Tricuspid Regurgitation with K-CLIP

Roughly 4% of the adult population presents tricuspid regurgitation (TR), a condition that might progress to severe or worse end-organ function, associated to hospitalizations...

PULSE Registry Subanalysis: Radial vs. Femoral Secondary Access

In view of its lower complications rate, the transfemoral approach is the most used in transcatheter aortic valve replacement (TAVR), vs. alternative access sites....

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Acute Coronary Syndrome with Multivessel Disease: Best Revascularization Strategy

The gold standard treatment for acute coronary syndrome (ACS), especially acute myocardial infarction (AMI) is primary angioplasty (PCI). However, 40 to 70% of ACS...

Improved Ejection Fraction in Chronic Total Occlusion?

Chronic total occlusions (CTO) represent a significant challenge in the current clinical practice, seeing as CTO percutaneous coronary intervention (PCI) is complex and involves...

TAVR and Surgical Bailout: Temporal Trends and Clinical Implications

The evolution of transcatheter aortic valve replacement (TAVR), both regarding its planning and execution, has resulted in minimally invasive interventions with high safety levels....